Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMPART adjuvant renal cell carcinoma trial
2017-002329-39Phase 3Unknown
- Sponsor
- University College London
- Start
- Aug 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in renal cell carcinoma (RCC) comparing Control / observation, Durvalumab and Durvalumab + tremelimumab (3 arms). Primary endpoint: Co-primary endpoints. Status: unknown.
02
Drugs
durvalumabtremelimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2017-002329-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002329-39.